Medicenna Historical Financial Ratios

MDNA Stock

CAD 1.77 0.10 5.99%

Medicenna Therapeutics is lately reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Medicenna Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Medicenna Financial Ratios Analysis

Medicenna TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Medicenna Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Medicenna financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Medicenna Therapeutics history.

Medicenna Therapeutics Financial Ratios Chart

At this time, Medicenna Therapeutics' Graham Number is very stable compared to the past year. As of the 27th of November 2024, Price Book Value Ratio is likely to grow to 25.50, while Book Value Per Share is likely to drop 0.07.

Average Payables Payables Turnover Cash Per Share Days Payables Outstanding

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Medicenna Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Medicenna Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2024 (projected)
Net Debt To EBITDA	0.91	2.06	1.61
Intangibles To Total Assets	0.002771	0.001674	0.00283

Net Debt To E B I T D A Intangibles To Total Assets

Medicenna Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Net Income Per Share	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Intangibles To Total Assets	Net Debt To E B I T D A
Ptb Ratio		0.25	-0.31	-0.4	0.39	-0.5	1.0	-0.4	-0.94	-0.33	0.22	0.31	0.34	0.5	0.5	0.34	-0.42	0.1	-0.99	0.34	0.4	0.74	0.34	-0.3	-0.32	0.35
Book Value Per Share	0.25		-0.11	-0.48	0.47	-0.55	0.25	-0.48	-0.04	-0.36	0.71	0.94	0.48	0.54	0.53	0.47	-0.66	0.02	-0.21	0.49	0.46	0.64	0.49	-0.02	-0.69	0.66
Free Cash Flow Yield	-0.31	-0.11		0.69	-0.78	0.66	-0.31	0.69	0.12	0.36	-0.31	-0.1	-0.74	-0.66	-0.65	-0.74	0.61	-0.51	0.35	-0.72	-0.73	-0.25	-0.72	0.7	0.25	-0.08
Operating Cash Flow Per Share	-0.4	-0.48	0.69		-0.91	0.85	-0.4	1.0	0.14	0.84	-0.72	-0.58	-0.87	-0.85	-0.84	-0.87	0.85	-0.28	0.44	-0.86	-0.72	-0.36	-0.86	0.73	0.5	-0.38
Average Payables	0.39	0.47	-0.78	-0.91		-0.79	0.39	-0.91	-0.16	-0.66	0.57	0.53	0.82	0.78	0.78	0.82	-0.87	0.24	-0.42	0.82	0.79	0.37	0.82	-0.63	-0.45	0.26
Capex To Depreciation	-0.5	-0.55	0.66	0.85	-0.79		-0.5	0.85	0.19	0.66	-0.47	-0.66	-0.97	-1.0	-1.0	-0.97	0.84	-0.5	0.53	-0.97	-0.86	-0.6	-0.97	0.59	0.63	-0.7
Pb Ratio	1.0	0.25	-0.31	-0.4	0.39	-0.5		-0.4	-0.94	-0.33	0.22	0.31	0.34	0.5	0.5	0.34	-0.42	0.1	-0.99	0.34	0.4	0.74	0.34	-0.3	-0.32	0.35
Free Cash Flow Per Share	-0.4	-0.48	0.69	1.0	-0.91	0.85	-0.4		0.14	0.84	-0.72	-0.58	-0.87	-0.85	-0.84	-0.87	0.85	-0.28	0.44	-0.86	-0.72	-0.36	-0.86	0.73	0.5	-0.38
Roic	-0.94	-0.04	0.12	0.14	-0.16	0.19	-0.94	0.14		0.16	-0.05	-0.07	-0.02	-0.19	-0.19	-0.02	0.16	0.09	0.93	-0.02	-0.12	-0.57	-0.02	0.16	0.11	-0.09
Net Income Per Share	-0.33	-0.36	0.36	0.84	-0.66	0.66	-0.33	0.84	0.16		-0.61	-0.51	-0.66	-0.67	-0.68	-0.66	0.72	0.07	0.4	-0.66	-0.45	-0.14	-0.66	0.8	0.57	-0.25
Payables Turnover	0.22	0.71	-0.31	-0.72	0.57	-0.47	0.22	-0.72	-0.05	-0.61		0.63	0.44	0.46	0.45	0.44	-0.6	-0.01	-0.19	0.44	0.29	0.33	0.44	-0.4	-0.43	0.26
Cash Per Share	0.31	0.94	-0.1	-0.58	0.53	-0.66	0.31	-0.58	-0.07	-0.51	0.63		0.58	0.64	0.64	0.58	-0.7	0.05	-0.29	0.59	0.53	0.67	0.59	-0.11	-0.74	0.78
Pocfratio	0.34	0.48	-0.74	-0.87	0.82	-0.97	0.34	-0.87	-0.02	-0.66	0.44	0.58		0.97	0.97	1.0	-0.85	0.5	-0.39	1.0	0.89	0.44	1.0	-0.65	-0.61	0.6
Interest Coverage	0.5	0.54	-0.66	-0.85	0.78	-1.0	0.5	-0.85	-0.19	-0.67	0.46	0.64	0.97		1.0	0.97	-0.84	0.49	-0.54	0.97	0.86	0.59	0.97	-0.6	-0.64	0.69
Capex To Operating Cash Flow	0.5	0.53	-0.65	-0.84	0.78	-1.0	0.5	-0.84	-0.19	-0.68	0.45	0.64	0.97	1.0		0.97	-0.85	0.47	-0.54	0.98	0.86	0.58	0.97	-0.6	-0.64	0.69
Pfcf Ratio	0.34	0.47	-0.74	-0.87	0.82	-0.97	0.34	-0.87	-0.02	-0.66	0.44	0.58	1.0	0.97	0.97		-0.85	0.5	-0.38	1.0	0.89	0.44	1.0	-0.65	-0.61	0.6
Days Payables Outstanding	-0.42	-0.66	0.61	0.85	-0.87	0.84	-0.42	0.85	0.16	0.72	-0.6	-0.7	-0.85	-0.84	-0.85	-0.85		-0.04	0.45	-0.86	-0.88	-0.47	-0.86	0.57	0.8	-0.42
Income Quality	0.1	0.02	-0.51	-0.28	0.24	-0.5	0.1	-0.28	0.09	0.07	-0.01	0.05	0.5	0.49	0.47	0.5	-0.04		-0.1	0.49	0.33	0.27	0.49	-0.18	0.18	0.48
Roe	-0.99	-0.21	0.35	0.44	-0.42	0.53	-0.99	0.44	0.93	0.4	-0.19	-0.29	-0.39	-0.54	-0.54	-0.38	0.45	-0.1		-0.38	-0.43	-0.68	-0.38	0.38	0.33	-0.32
Ev To Operating Cash Flow	0.34	0.49	-0.72	-0.86	0.82	-0.97	0.34	-0.86	-0.02	-0.66	0.44	0.59	1.0	0.97	0.98	1.0	-0.86	0.49	-0.38		0.9	0.45	1.0	-0.63	-0.62	0.61
Pe Ratio	0.4	0.46	-0.73	-0.72	0.79	-0.86	0.4	-0.72	-0.12	-0.45	0.29	0.53	0.89	0.86	0.86	0.89	-0.88	0.33	-0.43	0.9		0.53	0.9	-0.45	-0.7	0.51
Return On Tangible Assets	0.74	0.64	-0.25	-0.36	0.37	-0.6	0.74	-0.36	-0.57	-0.14	0.33	0.67	0.44	0.59	0.58	0.44	-0.47	0.27	-0.68	0.45	0.53		0.45	0.02	-0.52	0.74
Ev To Free Cash Flow	0.34	0.49	-0.72	-0.86	0.82	-0.97	0.34	-0.86	-0.02	-0.66	0.44	0.59	1.0	0.97	0.97	1.0	-0.86	0.49	-0.38	1.0	0.9	0.45		-0.63	-0.62	0.61
Earnings Yield	-0.3	-0.02	0.7	0.73	-0.63	0.59	-0.3	0.73	0.16	0.8	-0.4	-0.11	-0.65	-0.6	-0.6	-0.65	0.57	-0.18	0.38	-0.63	-0.45	0.02	-0.63		0.33	0.01
Intangibles To Total Assets	-0.32	-0.69	0.25	0.5	-0.45	0.63	-0.32	0.5	0.11	0.57	-0.43	-0.74	-0.61	-0.64	-0.64	-0.61	0.8	0.18	0.33	-0.62	-0.7	-0.52	-0.62	0.33		-0.54
Net Debt To E B I T D A	0.35	0.66	-0.08	-0.38	0.26	-0.7	0.35	-0.38	-0.09	-0.25	0.26	0.78	0.6	0.69	0.69	0.6	-0.42	0.48	-0.32	0.61	0.51	0.74	0.61	0.01	-0.54

Click cells to compare fundamentals

Medicenna Therapeutics Account Relationship Matchups

Medicenna Therapeutics fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Ptb Ratio	3.18	6.65	4.3	1.93	24.28	25.5
Book Value Per Share	1.13	0.77	0.38	0.46	0.0745	0.0708
Free Cash Flow Yield	(0.41)	(0.078)	(0.0603)	(0.26)	(0.22)	(0.13)
Operating Cash Flow Per Share	(0.42)	(0.31)	(0.28)	(0.2)	(0.23)	(0.25)
Pb Ratio	3.18	6.65	4.3	1.93	24.28	25.5
Free Cash Flow Per Share	(0.42)	(0.31)	(0.28)	(0.2)	(0.23)	(0.25)
Roic	(0.23)	(0.45)	(1.07)	0.11	(3.79)	(3.6)
Net Income Per Share	(0.26)	(0.35)	(0.42)	0.0239	(0.37)	(0.38)
Payables Turnover	0.0173	0.0178	0.0227	0.003092	0.002415	0.002295
Cash Per Share	0.0923	1.18	0.81	0.38	0.52	0.24
Pocfratio	(12.82)	(16.57)	(3.8)	(4.5)	(7.75)	(8.14)
Pfcf Ratio	(12.82)	(16.57)	(3.8)	(4.5)	(7.75)	(8.14)
Days Payables Outstanding	33.0K	42.9K	21.1K	20.5K	23.6K	43.3K
Income Quality	1.08	0.89	1.04	1.26	0.64	1.28
Roe	(0.23)	(0.45)	(1.09)	0.0525	(4.91)	(4.66)
Ev To Operating Cash Flow	(10.3)	(14.59)	(2.93)	(1.85)	(6.71)	(7.04)
Pe Ratio	(13.82)	(14.77)	(3.96)	36.82	(4.95)	(5.2)
Return On Tangible Assets	(0.22)	(0.41)	(0.97)	0.0425	(1.33)	(1.4)
Ev To Free Cash Flow	(10.3)	(14.59)	(2.93)	(1.85)	(6.71)	(7.04)
Earnings Yield	(0.0724)	(0.0677)	(0.25)	0.0272	(0.2)	(0.21)
Intangibles To Total Assets	0.002007	0.00168	0.002771	0.001674	0.002979	0.00283
Net Debt To E B I T D A	0.5	2.74	1.76	0.91	2.06	1.61
Current Ratio	20.85	10.26	8.92	9.57	6.66	4.79
Tangible Book Value Per Share	1.13	0.77	0.38	0.45	0.0737	0.07
Graham Number	0.65	2.58	2.45	1.9	0.49	0.9
Shareholders Equity Per Share	1.13	0.77	0.38	0.46	0.0745	0.0708
Graham Net Net	1.12	0.74	0.35	0.42	0.0562	0.0534
Enterprise Value Over E B I T D A	(11.15)	(12.95)	(3.06)	(1.43)	(5.84)	(6.13)
Price Earnings Ratio	(13.82)	(14.77)	(3.96)	36.82	(4.95)	(5.2)
Price Book Value Ratio	3.18	6.65	4.3	1.93	24.28	25.5
Price Earnings To Growth Ratio	(0.31)	(0.43)	(0.2)	(0.35)	0.003003	0.003153
Days Of Payables Outstanding	33.0K	42.9K	21.1K	20.5K	23.6K	43.3K
Price To Operating Cash Flows Ratio	(12.82)	(16.57)	(3.8)	(4.5)	(7.75)	(8.14)
Price To Free Cash Flows Ratio	(12.82)	(16.57)	(3.8)	(4.5)	(7.75)	(8.14)
Effective Tax Rate	(0.003899)	0.006131	(0.003056)	1.15	1.04	1.09
Company Equity Multiplier	1.05	1.11	1.13	1.24	3.69	3.87

Pair Trading with Medicenna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Medicenna Stock

0.67	TSLA	Tesla Inc CDR	Pair Corr
0.47	VISA	Visa Inc CDR	Pair Corr
0.44	PYPL	PayPal Holdings CDR	Pair Corr
0.39	INTC	INTEL CDR	Pair Corr

The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.

The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medicenna Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Medicenna Historical Financial Ratios

About Medicenna Financial Ratios Analysis

Medicenna Therapeutics Financial Ratios Chart

Average Payables

Payables Turnover

Medicenna Therapeutics fundamentals Correlations

Medicenna Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medicenna Therapeutics fundamentals Accounts

Pair Trading with Medicenna Therapeutics

Moving against Medicenna Stock

Other Information on Investing in Medicenna Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio
Ev To Operating Cash Flow	+ 1.0	Pocfratio
Ev To Free Cash Flow	+ 1.0	Pocfratio
Capex To Operating Cash Flow	+ 1.0	Interest Coverage

Capex To Operating Cash Flow	- 1.0	Capex To Depreciation
Interest Coverage	- 1.0	Capex To Depreciation
Roe	- 0.99	Pb Ratio
Roe	- 0.99	Ptb Ratio
Ev To Free Cash Flow	- 0.97	Capex To Depreciation
Ev To Operating Cash Flow	- 0.97	Capex To Depreciation